The combination therapy of glucagon‐like peptide‐1 (GLP‐1) RAs with basal insulin provides a more effective glucose management strategy for type 2 diabetes patients, particularly suitable for those requiring stable glucose fluctuations (Lin et al. 2022). Here, INS is linked to type 2 diabetes mellitus.